These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11529279)

  • 41. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.
    Holgate S; Buhl R; Bousquet J; Smith N; Panahloo Z; Jimenez P
    Respir Med; 2009 Aug; 103(8):1098-113. PubMed ID: 19362459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
    Schreiber J; Kopp MV; Korn S; Taube C; Buhl R
    Pneumologie; 2014 Mar; 68(3):187-92. PubMed ID: 24477463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A; Sternon J
    J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.
    Moss RB
    Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Omalizumab and other new drug therapies occupy a small space in asthma disease management.
    Curtiss FR
    J Manag Care Pharm; 2009 Apr; 15(3):289-93. PubMed ID: 19326961
    [No Abstract]   [Full Text] [Related]  

  • 49. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Therapy with omalizumab in patients with severe persistent allergic asthma: a real life data in Turkey].
    Bavbek S; Aydın O; Kepil Özdemir S; Yılmaz I; Celik GE; Demirel YS; Mungan D; Sin B; Kurşun N; Mısırlıgil Z
    Tuberk Toraks; 2010; 58(4):425-34. PubMed ID: 21341120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-IgE for chronic asthma.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2003; (3):CD003559. PubMed ID: 12917972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
    Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Omalizumab: not only for asthma.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relevance of IgE in the pathogenesis of allergy: the effect of an anti-IgE drug in asthma and other diseases.
    Domingo C; Pacheco A; Hinojosa M; Bosque M
    Recent Pat Inflamm Allergy Drug Discov; 2007 Jun; 1(2):151-64. PubMed ID: 19075978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monitoring Allergic Patients on Omalizumab with Free and Total Serum IgE Measurements.
    Hamilton RG
    J Allergy Clin Immunol Pract; 2016; 4(2):366-8. PubMed ID: 26968963
    [No Abstract]   [Full Text] [Related]  

  • 58. Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review.
    Storms W; Bowdish MS; Farrar JR
    Allergy Asthma Proc; 2012; 33(2):172-7. PubMed ID: 22525394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pratical aspects of anti-Ige therapy in severe allergic asthma].
    Taramarcaz P; Hauser C; Rochat T
    Rev Med Suisse; 2007 Apr; 3(108):1050-2, 1054-5. PubMed ID: 17552257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.